

# Maculopapular Cutaneous Mastocytosis Presentation with Elevated Serum Tryptase Levels (>20 µg/L): A Case Report

K Bhargavi<sup>1</sup>, K Swarajya Kumari<sup>2</sup>, Y Harsha Vardhan<sup>1</sup>, R Manideep<sup>3</sup>

<sup>1</sup>Junior Resident, Department of Pathology, Osmania Medical College, Hyderabad, Telangana, India, <sup>2</sup>Professor, Department of Pathology, Osmania Medical College, Hyderabad, Telangana, India, <sup>3</sup>Junior Consultant, Department of Histopathology, C Path Labs, Hyderabad, Telangana, India.

## Abstract

Cutaneous mastocytosis is a rare group of diseases characterised by the abnormal accumulation and proliferation of mast cells in the skin. There are three recognized forms: Diffuse cutaneous mastocytosis, cutaneous mastocytoma and, the most common form, maculopapular cutaneous mastocytosis. Pediatric patients are relatively rare to suffer from cutaneous mastocytosis. The presented case of 9-month-old male infant with respiratory distress and coughing for 2 days, along with dark raised and flat lesions all over his body for 4 months. Skin biopsy showed uniformly spindle-shaped cohesive aggregates of mast cells filling the papillary and mid dermis. A modest increase in perivascular mast cells was identified. Toluidine blue wet stains of the tissue showed a striking cluster of mast cells in the dermis observed in purple to red color. Even though serum tryptase >20 µg/L, there is no evidence of marrow involvement. A retrospective review of literature on pediatric cutaneous mastocytosis in Indian scenarios demonstrated that serum tryptase levels are significantly higher.

**Key words:** Bone marrow, Cutaneous mastocytosis, Tryptase

## INTRODUCTION

Mastocytosis is a disorder of mast cells characterized by multifocal compact clusters or cohesive aggregates. The disorder is heterogeneous with skin or multi-organ involvement (cutaneous/systemic involvement). In cutaneous mastocytosis, atypical/normal mast cells accumulate in the dermis due to increased proliferation and decreased apoptosis. A recent WHO classification recognizes them as diffuse cutaneous mastocytosis, cutaneous mastocytoma, and maculopapular cutaneous mastocytosis, the most common form.

## CASE REPORT

A 9-month-old male infant is brought with a complaint of respiratory distress, fever, and cough for 2 days.

Complain of dark to red colored raised and flat lesions associated with itching all over the body for 4 months. Lesions started initially over the face and neck and slowly progressed to involve the trunk over 2 months. Lesions are erythematous and later hyperpigmented and associated with itching. Past history of chicken pox, no relevant other histories (vomiting/food allergy/abdominal pain/diarrhoea/family history). On physical examination Figure1 illustrates, multiple erythematous to hyperpigmented macules and plaques are present on the face, trunk, scalp, and neck. No involvement of hair, nails, oral, and genital mucosa. Darier's sign is positive.

Laboratory workup showed elevated serum tryptase level (27.9 µg/L, Method: floenzyme immunoassay), and peripheral blood smear reveals mild eosinophilia ( $1.22 \times 10^3$  micro/L) with thrombocytosis. Ultrasonography works up to finding negative for organomegaly. Subsequently, a skin biopsy was performed.

Histopathological studies as illustrated in Figure 2 showed epidermal spongiosis with basal layer hyperpigmentation. Uniformly spindle-shaped cohesive aggregates of mast cells fill the papillary and mid dermis. A modest increase in perivascular atypical mast cells was identified. Toluidine

Access this article online



www.ijss-sn.com

**Month of Submission** : 01-2023  
**Month of Peer Review** : 02-2023  
**Month of Acceptance** : 02-2023  
**Month of Publishing** : 03-2023

**Corresponding Author:** K Bhargavi, Department of Pathology, Osmania Medical College, Hyderabad, Telangana, India.

**Table 1: Comparisons of MPCM studies with elevated tryptase level**

Study	Carter et al. <sup>[16]</sup> (>20 µg/L)	Schwartz et al. <sup>[11]</sup> (>20 µg/L)	Sathishkumar et al. <sup>[17]</sup> (>24 µg/L)
MPCM cases count	12.5%	23%	30.7%

blue wet stains of the tissue showed a striking cluster of mast cells at the dermis in purple to red in color. In view of raised tryptase levels (>20 µg/L) to rule out systemic mastocytosis, bone marrow studies were performed. Diluted aspirates show an increase in eosinophilic precursors and mast cells. Mastocytosis can present with hypogranular mast cells (atypical) which are appreciated by CD117, but aspirated smears are negative for mast cell clusters. Based on the above evidence, cutaneous mastocytosis is rendered and the toddler was kept under follow-up.

## DISCUSSION


Cutaneous mastocytosis is identified by the clinical presentation of skin lesion associated with Darier's sign in addition to the absence of systemic mastocytosis. Histological presence of increased mast cells (in clusters) in the dermis by 4–8-fold in the lesion compared to the skin of healthy subjects or increase of mast cells by 2–3-fold compared with those in the skin of patients with inflammatory cutaneous disease.<sup>[1-7]</sup>

Maculopapular cutaneous mastocytosis (urticaria pigmentosa) is the most common manifestation of mastocytosis among children. MPCM is classified into monomorphic and polymorphous lesions clinically. Often, children with polymorphous MPCM exhibit brown or red lesions of different sizes with sharp or indistinct margins, as well as flat or elevated lesions. Over time, lesions commonly spread to the upper trunk, distal extremities, and lateral neck, starting on the thigh, axilla, or lower trunk. The skin on the face is usually spared.<sup>[8,9]</sup> There is a wide range of lesions among patients, ranging from fewer than 10 lesions to almost universal coverage, and the number may correlate with systemic involvement, as well as with serum tryptase.<sup>[10]</sup>

Most of the cutaneous mastocytosis had (B12) tryptase levels <20 µg/L, while systemic disease patients had levels above 20 µg/L.<sup>[11]</sup> The presence of MPCM with serum tryptase levels above 20 µg/L raises suspicions of systemic mastocytosis, subsequently leading to bone marrow testing, which is more likely to yield negative results. Routine Peripheral blood smears in mastocytosis are often normal with minority of cases show evidence of abnormal proliferation of cells of one or more myeloid lineage (neutrophils, eosinophils, basophils, monocytes, or thrombocytosis).<sup>[12,13]</sup> cutaneous mastocytosis in pediatric population has hypocellular smear with increased



**Figure 1: Clinical presentation of maculopapular cutaneous mastocytosis on inspection. (a) Inspection of the child on ventral and dorsal (b) Aspect shows hyperpigmented macules and plaques involving face, trunk, scalp and neck**



**Figure 2: Microscopy of Maculopapular cutaneous mastocytosis. (a and d) (scale 200 µm) showing uniformly spindle-shaped cohesive aggregate of mast cells filled the papillary area and the mid dermis. (b) (scale 200 µm) Toluidine blue staining of skin highlights mast cells in purple colour. (c) (scale 50 µm) section from skin showing CD117 IHC highlighting mast cells in epidermis in a exhausted skin block of cutaneous**

hematogones in bone marrow aspirate smears.<sup>[14]</sup> There may be mild erythroid and megakaryocytic dysplasia. Bone marrow biopsy shows focal perivascular and peritrabecular location of mast cells, eosinophils, and early myeloid cells.<sup>[15]</sup> Comparing with various studies as showed in the Table1 above, Southern Indian population are tend to have higher serum tryptase levels.

MPCM is less likely associated with bone marrow involvement or organomegaly, but if present, they are usually associated more with hepatomegaly. In follow-

up bone marrow studies in MPCM, its observed that biopsies are normocellular to hypocellular with 27% of cases showing increased mast cells (typical) in addition 9% of cases demonstrated mast cell aggregates (<15 cell). All the cases were resolved or partially resolved with no transformation into systemic mastocytosis in follow-up biopsy after 20-years.<sup>[18]</sup>

## CONCLUSION

It has been observed that few pediatric MPCM cases with relatively higher or marginally elevated serum tryptase levels (>20 µg/L) at initial presentation are less likely to have underline systemic disease (especially in the South Indian population). The threshold point of suspecting underlining systemic disease by serum tryptase level is relatively higher in the South Indian population. Perhaps it's better to keep such cases under annual follow-up check-ups and teleconsultations once every 6 months rather than recommended for bone marrow studies to rule out systemic mastocytosis, especially at the initial encounter.

More analytical studies should be done to judge the threshold point on serum tryptase levels to know when should we suspect underlining systemic mastocytosis in the Southern Indian pediatric population.

## ACKNOWLEDGMENTS

I would like to express my sincere gratitude to Assistant Professor Dr. Vandana for her invaluable guidance and support during the process of drafting this research article.

I am also deeply thankful to my dermatology clinical colleague, Dr. Vijay, who is a Junior Resident at Osmania Medical College, for his valuable assistance in providing me with essential clinical details.

## REFERENCES

1. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. *Leuk Res* 2001;25:519-28.
2. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, *et al.* Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria. *Eur J Clin*

- Invest 2007;37:435-53.
3. Rabenhorst A, Schlaak M, Heukamp LC, Forster A, Theurich S, von Bergwelt-Baildon M, *et al.* Mast cells play a protumorigenic role in primary cutaneous lymphoma. *Blood* 2012;120:2042-54.
4. Ribatti D, Nico B, Finato N, Crivellato E, Beltrami CA. Co-localization of tryptase and cathepsin-G in mast cells in cutaneous mastocytosis. *Cancer Lett* 2009;279:209-12.
5. Brockow K, Akin C, Huber M, Scott LM, Schwartz LB, Metcalfe DD. Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: Correlation with dermal mast-cell numbers and mast-cell tryptase. *J Allergy Clin Immunol* 2002;109:82-8.
6. Irani AA, Garriga MM, Metcalfe DD, Schwartz LB. Mast cells in cutaneous mastocytosis: Accumulation of the MCTC type. *Clin Exp Allergy* 1990;20:53-8.
7. Garriga MM, Friedman MM, Metcalfe DD. A survey of the number and distribution of mast cells in the skin of patients with mast cell disorders. *J Allergy Clin Immunol* 1988;82:425-32.
8. Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, *et al.* Cutaneous manifestations in patients with mastocytosis: Consensus report of the European competence network on mastocytosis; The American Academy of Allergy, Asthma and Immunology; and The European Academy of Allergology and Clinical Immunology. *J Allergy Clin Immunol* 2016;137:35-45.
9. Wiechers T, Rabenhorst A, Schick T, Preussner LM, Förster A, Valent P, *et al.* Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. *J Allergy Clin Immunol* 2015;136:1581-90.e3.
10. Brockow K, Akin C, Huber M, Metcalfe DD. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: Relationship to symptomatology, tryptase levels, and bone marrow pathology. *J Am Acad Dermatol* 2003;48:508-16.
11. Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS, *et al.* The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. *J Clin Invest* 1995;96:2702-10.
12. Horny HP, Ruck M, Wehrmann M, Kaiserling E. Blood findings in generalized mastocytosis: Evidence of frequent simultaneous occurrence of myeloproliferative disorders. *Br J Haematol* 1990;76:186-93.
13. Parker RI. Hematologic aspects of mastocytosis II: Management of hematologic disorders in association with systemic mast cell disease. *J Invest Dermatol.* 1991;96:52S-3, discussion 53S-4.
14. Carter MC, Metcalfe DD, Clark AS, Wayne AS, Maric I. Abnormal bone marrow histopathology in paediatric mastocytosis. *Br J Haematol* 2015;168:865-73.
15. Parker RI. Hematologic aspects of mastocytosis: I: Bone marrow pathology in adult and pediatric systemic mast cell disease. *J Invest Dermatol* 1991;96:47S-51; discussion 50S, 60S-5S.
16. Carter MC, Clayton ST, Komarow HD, Brittain EH, Scott LM, Cantave D, *et al.* Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis. *J Allergy Clin Immunol* 2015;136:1673-9.e3.
17. Sathishkumar D, Balasundaram A, Mathew SM, Mathew L, Thomas M, Balasubramanian P, *et al.* Clinicopathological profile of childhood onset cutaneous mastocytosis from a tertiary care center in South India. *Indian Dermatol Online J* 2021;12:706-13.
18. Uzzaman A, Maric I, Noel P, Kettelhut BV, Metcalfe DD, Carter MC. Pediatric-onset mastocytosis: A long term clinical follow-up and correlation with bone marrow histopathology. *Pediatr Blood Cancer* 2009;53:629-34.

**How to cite this article:** Bhargavi K, Kumari KS, Vardhan YH, Manideep R. Maculopapular Cutaneous Mastocytosis Presentation with Elevated Serum Tryptase Levels (>20 µg/L): A Case Report. *Int J Sci Stud* 2023;10(12):5-7.

**Source of Support:** Nil, **Conflicts of Interest:** None declared.